CD44: CD44 antigen
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CD44, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Antibody-drug conjugate 1
- Other 1
Approved0
Phase 30
Phase 21
Phase 11
Preclinical or unknown1
| Bivatuzumab | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Antibody | Binding agentCD44 antigen binding agent | 0 |
| Bivatuzumab mertansine | Phase 1 | — | Antibody-drug conjugate | Binding agentCD44 antigen binding agent | 0 |
| PF-03475952 | Preclinical or unknown | — | Other | InhibitorCD44 antigen inhibitor | 0 |
- Nephrolithiasis, calcium oxalate0.52
- Calcium oxalate urolithiasis0.52
- Uterine corpus leiomyoma0.48
- Systemic lupus erythematosus0.47
- Autoimmune disease0.33
- Glomerulonephritis0.28
- Thyroiditis0.28
- Hypothyroidism0.26
- Hashimoto thyroiditis0.26
- Liver disorder0.25
- Thyroid gland disorder0.22
- Neurodegenerative disease0.20
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3232692, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P16070, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets